Humacyte Inc HUMA

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

NDAQ:HUMA - Post by User

Humacyte Inc

<< Previous

Bullboard Posts

Post by whytestockson Dec 20, 2024 10:00am

18 Views

Post# 36372025

FDA Approves Humacyte's SYMVESS for Extremity Vascular Traum

NEWS: $HUMA FDA Approves Humacyte's SYMVESS for Extremity Vascular Trauma Treatment2024-12-20 08:20:59 ET DENVER, Colo., Dec 20, 2024 ( 247marketnews.com )- Humacyte (NASDAQ: HUMA ) reported that the U.S. Food and Drug Administration (FDA) granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod), a first-in-class bioengineered human tissue, fo...HUMA - FDA Approves Humacyte's SYMVESS for Extremity Vascular Trauma Treatment

<< Previous

Bullboard Posts

Critical materials crisis: Diversifying away from China’s monopoly